Emerging and Established Therapeutic Targets in Cancer Immunotherapy
From Bench to Bedside
- 1st Edition - May 1, 2027
- Latest edition
- Editors: Eyad Elkord, Hayam Hamdy
- Language: English
Emerging and Established Therapeutic Targets in Cancer Immunotherapy: From Bench to Bedside provides a comprehensive overview of emerging and established therapeutic targets and st… Read more
Description
Description
Key features
Key features
- Examines emerging and established therapeutic targets, including immune checkpoints, neoantigens, and cellular targets in cancer immunotherapy
- Explores innovative immunotherapeutic approaches, including cancer vaccines, multispecific antibodies, and next-generation CAR-T cell therapies
- Discusses mechanisms of therapeutic resistance and strategies for improving the efficacy of combination immunotherapies
- Analyzes tumor microenvironment modulation, including targeting myeloid-derived suppressor cells, regulatory T cells, and stromal components
- Highlights the roles of tumor metabolism, epigenetic regulation, the microbiome, multi-omics, and artificial intelligence in immunotherapy development
Readership
Readership
Table of contents
Table of contents
2. Immune checkpoint inhibitors: New targets and approaches to overcome resistance
3. T regulatory cells as therapeutic targets in cancer immunotherapy
4. Microbiome modulation in cancer immunotherapy
5. New antigens and cancer vaccine therapies: Progress, challenges, and emerging strategies
6. Tumor mutation burden and potential targets of immunotherapy
7. Autophagy and hypoxia as therapeutic targets in cancer immunotherapy
8. Myeloid-derived suppressor cells as promising targets in cancer immunotherapy
9. Latest advances in combination therapy to enhance cancer immunotherapy
10. Strategies for enhancing T-cell receptor-based cancer immunotherapy
11. Next generation CAR-T cell therapies: Novel targets and strategies to enhance safety and efficacy
12. Immunoregulatory crosstalk in the suppressive tumor microenvironment
13. Long noncoding RNAs in the regulation of immune responses in cancer immunotherapy
14. Development of novel antibodies and application of multi-specific antibodies in tumor immunotherapy
15. Neoantigens and cancer germline antigens as novel targets for cancer immunotherapy
16. Understanding and overcoming resistance to cancer immunotherapy
17. Emerging immunomodulatory targets for remolding tumor immunity
18. Recent advances in targeting innate immune cells and pathways for cancer immunotherapy
19. Epigenetic targets for enhancing cancer immunotherapy
20. Small molecules and biologics for modulating the tumor immune microenvironment
21. Reprogramming the tumor metabolic microenvironment for immunotherapy
22. Multi-omics approaches to identify personalized targets for cancer immunotherapy
23. Artificial Intelligence and computational immunology: Emerging tools for target discovery in cancer immunotherapy
24. Regulatory and manufacturing considerations in the development of immunotherapy targets: From bench to bedside
Product details
Product details
- Edition: 1
- Latest edition
- Published: May 1, 2027
- Language: English
About the editors
About the editors
EE
Eyad Elkord
Professor Elkord is a leading immunologist and Director of the Suzhou Key Lab of Biomedical Sciences and Translational Immunology, as well as an honorary professor at the University of Salford. Renowned for his expertise in cancer immunology and immunotherapy, he has been listed among Stanford’s top 2% influential scientists for five consecutive years, ranking in the top 0.26% in immunology. Recognized as one of Elsevier’s Most Highly Cited Chinese Researchers 2024, his impactful work includes over 150 publications with more than 13,500 citations. He serves on the editorial boards of prominent journals such as Frontiers in Immunology & Oncology and BMC Cancer and is a respected reviewer for numerous international publications and funding agencies. His groundbreaking research significantly advances the understanding of cancer immunology, making him a highly influential figure in the field.
HH
Hayam Hamdy
Dr Hayam Hamdy is currently a postdoctoral fellow at the School of Life Sciences, Yunnan University, China, and a lecturer in the Department of Forensic Medicine and Toxicology at New Valley University, Egypt. Her research focuses on cancer biology, hepatocarcinogenesis, tumour microenvironment, molecular oncology, and cancer immunotherapy. Her work particularly emphasises therapeutic targets, immune regulation, immune checkpoint pathways, inflammatory signalling, and mechanisms underlying tumour progression and therapy resistance. She has contributed to research in cancer immunotherapy, tumour immunology, immune checkpoint regulation, and tumour microenvironment interactions, reflecting strong expertise in immunotherapeutic strategies and translational cancer research. She has an established publication record in high-impact international journals and extensive experience in molecular biology, immunological assays, in vivo cancer models, and interdisciplinary translational cancer research. She has also actively participated in multidisciplinary research collaborations and in the development of scientific manuscripts in the fields of cancer biology and immunology.